PET Scan (Positron Emission Tomography): Clinical Guide to Diagnostic Imaging — Cost, Top Hospitals & Success Rates | MyMedicPlus

Positron Emission Tomography (PET) is a functional nuclear medicine imaging modality that maps physiological and biochemical processes at the molecular level. Unlike structural imaging (CT or MRI), which depicts anatomy, PET reveals metabolic activity — enabling detection of disease before structural changes become visible on conventional imaging.

The standard clinical PET examination is almost universally performed as a combined PET/CT scan. The CT component provides anatomical context and attenuation correction for the PET data, while the PET component provides metabolic information. Modern integrated scanners acquire both data sets simultaneously in a single session lasting 20–30 minutes after a 60-minute uptake period.

The most widely used PET tracer is 18F-fluorodeoxyglucose (FDG), a radiolabelled glucose analogue. The physical principle exploits the Warburg effect: malignant cells, rapidly dividing tissues, and inflammatory cells upregulate GLUT-1 glucose transporters and hexokinase activity, causing disproportionately high glucose uptake compared to surrounding normal tissue. FDG is taken up and phosphorylated intracellularly but not further metabolised, resulting in intracellular trapping and accumulation that can be detected by the PET scanner.

The radioactive fluorine-18 isotope (half-life 109.8 minutes) undergoes positron emission decay: the emitted positron travels a short distance in tissue (mean 0.6 mm) before annihilating with an electron to produce two 511 keV gamma photons emitted in exactly opposite directions. PET detectors surrounding the patient register simultaneous (coincident) detection of these photon pairs, enabling three-dimensional localisation of the radiotracer.

Quantification of tracer uptake is expressed as the Standardised Uptake Value (SUV), calculated as the ratio of tissue radioactivity concentration to the injected dose divided by body weight. SUVmax (the maximum voxel value in a region) is the most commonly reported metric and is used for lesion characterisation, therapy response assessment, and prognostication across multiple oncological applications.

FDG-PET/CT and specialised PET tracers are indicated across a wide spectrum of oncological, neurological, and cardiological conditions:

• Oncological staging and restaging — FDG-PET/CT is the standard of care for initial staging and post-treatment restaging in lymphoma, lung cancer, oesophageal cancer, colorectal cancer, melanoma, and many other solid tumours. It detects nodal and distant metastases not apparent on CT, upstaging or downstaging approximately 20–30% of patients compared to CT alone.
• Lymphoma: Deauville scoring — For Hodgkin and diffuse large B-cell lymphoma, the 5-point Deauville scale compares FDG uptake in residual masses to mediastinal blood pool (score 1–2: complete metabolic response) and liver activity (score 3: partial response; scores 4–5: insufficient response). Interim PET after two cycles of ABVD in Hodgkin lymphoma is used to guide escalation or de-escalation of chemotherapy.
• PERCIST vs RECIST response assessment — RECIST 1.1 uses lesion size change on CT to classify tumour response. PERCIST 1.0 (PET Response Criteria in Solid Tumours) uses change in SULpeak (SUV lean-body-mass corrected) to classify complete metabolic response (CMR), partial metabolic response (PMR), stable metabolic disease (SMD), or progressive metabolic disease (PMD), often detecting response earlier than anatomical shrinkage.
• Prostate cancer: 68Ga-PSMA PET/CT — PSMA (prostate-specific membrane antigen) is overexpressed on prostate cancer cells. 68Ga-PSMA-11 and 18F-DCFPyL PET/CT detect recurrence at PSA levels as low as 0.2 ng/mL and are now preferred over conventional bone scan and CT for biochemical recurrence assessment.
• Neuroendocrine tumours: 68Ga-DOTATATE PET/CT — Somatostatin receptor-expressing neuroendocrine tumours (including carcinoid, phaeochromocytoma, paraganglioma) are detected with high sensitivity using 68Ga-DOTATATE, superior to conventional MIBG scintigraphy.
• Cardiac viability assessment — 18F-FDG cardiac PET identifies hibernating myocardium (metabolically active but mechanically dysfunctional tissue) that may recover contractile function after coronary revascularisation, guiding patient selection for bypass surgery.
• Dementia: Amyloid and tau PET — 18F-florbetapir, 18F-florbetaben, and 18F-flutemetamol detect amyloid-beta plaques in Alzheimer disease. 18F-flortaucipir maps tau neurofibrillary tangles. Both tracers enable ante-mortem pathological characterisation of dementia aetiology.

PET scanning is indicated for a broad range of patients, but careful preparation is essential to ensure diagnostic image quality:

• Fasting requirement — Patients must fast for a minimum of 6 hours before FDG injection (water is permitted). Fasting suppresses physiological insulin-stimulated glucose uptake by skeletal muscle, which would otherwise compete with tumour uptake and reduce tumour-to-background contrast. For cardiac viability studies, the protocol is reversed: glucose loading before FDG injection to maximise myocardial FDG uptake in hibernating tissue.
• Blood glucose control — Pre-injection blood glucose must be <8.0 mmol/L (144 mg/dL) for oncological PET/CT. Hyperglycaemia competitively inhibits FDG uptake by tumour cells (as endogenous glucose competes for GLUT transporters) and increases background noise. In diabetic patients, imaging is ideally performed in the morning before insulin or antidiabetic medications; metformin is withheld for 24–48 hours before scanning by some protocols to reduce colonic FDG uptake.
• Physical inactivity before scanning — Strenuous physical exercise must be avoided for 24–48 hours before scanning to prevent physiological FDG uptake in skeletal muscle, which can obscure pathological uptake or create false-positive findings.
• Warm environment during uptake — Patients rest in a warm, quiet room during the 60-minute FDG uptake phase to suppress brown adipose tissue (BAT) activity in the neck, supraclavicular fossae, and paravertebral regions. Cold exposure activates BAT and causes intense FDG uptake that can simulate or mask lymph node pathology.
• Renal function for CT contrast — If intravenous CT contrast is administered alongside PET, estimated GFR ≥45 mL/min/1.73m2 is generally required. PET itself does not require contrast.
• Contraindications and precautions — Pregnancy is a relative contraindication (ionising radiation to the foetus). Breastfeeding mothers should suspend feeding for 12–24 hours after FDG injection. Claustrophobic patients may require anxiolytic premedication. Morbidly obese patients (>200 kg) may exceed scanner bore weight limits.

The diagnostic information obtained from a PET scan is determined by the tracer selected. An expanding portfolio of PET radiopharmaceuticals enables highly specific molecular targeting:

• 18F-FDG (Fluorodeoxyglucose) — The workhorse tracer for oncology, infection, and inflammation imaging. Approximately 90% of all PET scans use FDG. Standard oncological protocol: 60-minute uptake at rest in a warm room, followed by emission acquisition from the skull base to mid-thigh. Dose: 2–4 MBq/kg (typical adult dose 200–300 MBq). Effective radiation dose: approximately 7 mSv (comparable to 3.5 years of background radiation).
• 68Ga-PSMA-11 (Gallium PSMA) — Gallium-68 labelled PSMA ligand for prostate cancer staging and biochemical recurrence detection. Shorter half-life (68 minutes) than 18F-FDG; produced by on-site germanium-68/gallium-68 generator, enabling use without on-site cyclotron. FDA approved (Illuccix) and widely used globally. Superior to CT and bone scan for detection at PSA ≥0.2 ng/mL post-prostatectomy.
• 18F-DCFPyL (Pylarify) — An 18F-labelled PSMA PET tracer with longer half-life (110 minutes) than 68Ga-PSMA, enabling distribution from centralised cyclotron facilities. FDA approved 2021 for prostate cancer recurrence localisation.
• 68Ga-DOTATATE (Lutathera workup, Netspot) — Somatostatin receptor subtype 2 (SSTR2)-binding tracer for neuroendocrine tumour detection and PRRT candidacy assessment. FDA and EMA approved. Substantially superior sensitivity compared to 111In-Octreotide SPECT.
• 18F-florbetapir (Amyvid), 18F-florbetaben (Neuraceq), 18F-flutemetamol (Vizamyl) — Amyloid PET tracers binding to neuritic plaques in Alzheimer disease. Approved for amyloid burden assessment in patients with cognitive impairment when diagnosis is uncertain. Positive scan does not confirm Alzheimer disease in isolation; clinical correlation required.
• 18F-flortaucipir (Tauvid) — FDA-approved tau PET tracer for adult patients with cognitive impairment. Enables differential diagnosis between Alzheimer disease (medial temporal and parieto-occipital tau) and other tauopathies (frontotemporal patterns).
• 18F-NaF (sodium fluoride) — Bone-seeking tracer with superior sensitivity and specificity compared to 99mTc-MDP bone scintigraphy for detection of skeletal metastases. Particularly useful in prostate cancer, breast cancer, and sarcoma.

FDG-PET/CT and specialised PET tracers offer diagnostic advantages that translate directly into improved patient management and clinical outcomes:

• Superior sensitivity for distant metastases — FDG-PET/CT detects unsuspected distant metastases in 15–30% of patients with newly diagnosed non-small cell lung cancer, oesophageal cancer, or head and neck cancer staged by CT alone, altering management from curative to palliative intent and avoiding futile surgery.
• Earlier response assessment — Metabolic response on FDG-PET/CT may be apparent after one to two cycles of chemotherapy, weeks before anatomical shrinkage measurable by RECIST. This enables early treatment escalation, de-escalation, or switch in lymphoma, allowing personalised adaptive therapy.
• Whole-body staging in a single session — A single PET/CT acquisition from skull base to mid-thigh covers all potential sites of metastatic spread simultaneously, eliminating the need for multiple separate imaging studies (CT chest/abdomen/pelvis plus bone scan) and reducing total radiation exposure compared to the combined multi-modality alternative.
• High specificity of PSMA PET for prostate cancer — PSMA PET/CT detects biochemical recurrence in 76% of men with PSA ≥0.2 ng/mL post-prostatectomy compared to 26% for conventional imaging (ProPSMA trial, Hofman et al., Lancet 2020), enabling curative salvage radiotherapy to be directed accurately to the site of recurrence.
• Guiding biopsy and treatment planning — PET identifies metabolically most active regions within heterogeneous tumours, guiding biopsy to highest-grade areas and enabling radiotherapy dose painting (dose escalation to FDG-avid subvolumes while reducing dose to metabolically inactive areas).
• Cardiac viability assessment — FDG cardiac PET correctly identifies hibernating myocardium with sensitivity and specificity >85%, enabling cardiologists to select patients most likely to benefit from coronary bypass surgery in ischaemic cardiomyopathy, avoiding high-risk surgery in patients with predominantly scarred non-viable myocardium.
• Infection and inflammation localisation — FDG-PET/CT localises occult infection sites in fever of unknown origin, prosthetic valve endocarditis, large-vessel vasculitis, and osteomyelitis with high accuracy.

PET scanning is safe for the vast majority of patients, but involves ionising radiation and specific limitations that clinicians and patients should understand:

• Radiation exposure — A standard FDG-PET/CT delivers approximately 7 mSv effective dose from the FDG (approximately 5 mSv) plus 2–4 mSv from the low-dose CT component. This is equivalent to approximately 3–4 years of typical background radiation and carries an estimated incremental lifetime cancer risk of approximately 1 in 2,000 for adults. The benefit in oncological diagnosis substantially outweighs this risk for most patients.
• False positive FDG uptake — Because FDG accumulates in any glucose-avid tissue, not exclusively malignant cells, the following physiological and benign conditions cause increased FDG uptake that may mimic malignancy: brown adipose tissue (neck, supraclavicular, paravertebral), active skeletal muscle, post-radiotherapy inflammation (within 3–6 months), granulomatous diseases (sarcoidosis, tuberculosis), healing fractures, and reactive lymph nodes. These must be distinguished from malignancy by experienced nuclear medicine physicians.
• False negative results — Low-grade, well-differentiated tumours (prostate adenocarcinoma with low Gleason score, low-grade NET, mucinous tumours, small (<8 mm) lesions) may be FDG-negative due to low metabolic activity or lesion size below PET spatial resolution (approximately 4–5 mm). Standard FDG-PET is not recommended for primary prostate cancer detection for this reason.
• Claustrophobia — The combined PET/CT scanner bore has a diameter of approximately 70 cm. Claustrophobic patients may experience anxiety; premedication with oral anxiolytic (e.g., lorazepam 0.5–1 mg) can be prescribed in advance.
• Radiation precautions post-scan — After FDG injection, patients are mildly radioactive. IRMER/IRR regulations require avoiding prolonged close contact with pregnant women and young children (<3 years) for approximately 6 hours post-injection, until FDG activity has decayed.
• Contrast reactions — Intravenous iodinated CT contrast carries a small risk of anaphylactoid reactions (approximately 0.04% severe) and contrast nephropathy. Pre-medication with corticosteroids and antihistamines is used for patients with prior mild reactions.

The clinical value of a PET scan is realised through appropriate interpretation and integration of results into multidisciplinary management:

• Timing of response assessment PET — Post-chemotherapy FDG-PET/CT should be performed no sooner than 6–8 weeks after completing chemotherapy (or 8–12 weeks after radiotherapy) to avoid false-positive inflammatory uptake from treatment effect. Earlier scans risk overestimating residual disease.
• Interim PET in Hodgkin lymphoma — Interim PET is performed after 2 cycles of ABVD in advanced Hodgkin lymphoma. A Deauville score 1–2 (negative) allows de-escalation to AVD (omitting bleomycin, reducing pulmonary toxicity). Deauville 4–5 (positive) triggers escalation to BEACOPPescalated. This adaptive strategy, validated in the RATHL trial, maintains disease control while reducing late toxicity.
• End-of-treatment assessment — PET/CT after completing all planned therapy determines whether complete metabolic response (CMR) has been achieved. CMR on end-of-treatment PET is the strongest independent predictor of progression-free survival and overall survival in both Hodgkin and diffuse large B-cell lymphoma.
• Surveillance imaging — For many solid tumours, routine PET surveillance after achieving remission is not recommended due to radiation burden and low yield. Exception includes high-risk melanoma and thyroid cancer where FDG-PET or 18F-NaF PET may detect recurrence before clinical symptoms.
• PSMA PET follow-up in prostate cancer — After PSMA PET-directed salvage radiotherapy, PSA should be monitored at 3-monthly intervals. Repeat PSMA PET at biochemical recurrence (>0.2 ng/mL rise above nadir post-salvage RT) guides further management decisions including systemic therapy or oligometastatic retreatment.
• Amyloid PET follow-up — A positive amyloid PET scan in a patient with mild cognitive impairment should trigger neurologist review, consideration of disease-modifying therapy trials (e.g., anti-amyloid antibodies including lecanemab), and regular cognitive assessment at 6–12 month intervals.

PET/CT scanning is among the more costly diagnostic imaging procedures, reflecting the specialised equipment, short-lived radiopharmaceuticals, and expert interpretation required. Understanding cost drivers helps patients and clinicians plan appropriately:

• Equipment and infrastructure costs — A PET/CT scanner costs approximately $2–5 million USD. On-site cyclotron (for 18F-tracers) adds $3–5 million. 68Ga-generator-based tracers (PSMA, DOTATATE) eliminate cyclotron dependency but generators must be replaced every 6–12 months ($30,000–$80,000 each). These capital costs are reflected in per-scan charges.
• Radiopharmaceutical cost — FDG is the least expensive tracer, with per-patient dose cost of $50–$200 USD. Gallium-68 PSMA and DOTATATE doses cost $300–$800 USD. 18F-florbetapir (Amyvid) for amyloid PET costs approximately $3,200 USD per dose in the US, significantly limiting access outside clinical trials.
• UK NHS coverage — FDG-PET/CT for NICE-approved oncological indications is funded by NHS England. Indications include lung, oesophageal, colorectal, head and neck, lymphoma, and melanoma staging. 68Ga-PSMA PET/CT for prostate cancer is funded in the UK. Cardiac PET viability and amyloid PET have more limited NHS coverage and may require prior approval.
• Private costs (UK) — Private FDG-PET/CT in the UK ranges from £1,500–£3,000. Specialised tracers (PSMA, DOTATATE, amyloid) range from £2,000–£5,000 due to additional radiopharmaceutical costs.
• Medical tourism options — India offers FDG-PET/CT for approximately $300–$600 USD at top-tier oncology centres including AIIMS, Tata Memorial, and Apollo hospitals, representing savings of 70–80% compared to UK private rates. South Korea, Thailand, and Turkey also provide cost-effective PET imaging at internationally accredited centres.
• Insurance considerations — Most international health insurers cover FDG-PET/CT for staging established malignancies. Pre-authorisation is almost always required. Coverage for novel tracers (amyloid PET, tau PET) varies widely by policy and jurisdiction.

PET/CT is one component of a broader diagnostic and staging toolkit. Alternatives or complementary modalities are selected based on the clinical question, patient factors, and tracer availability:

• Contrast-enhanced CT — The most widely available, fast, and cost-effective cross-sectional imaging modality. Excellent for anatomical characterisation, lesion measurement (RECIST), and identifying organ-based metastases. However, CT cannot distinguish viable tumour from necrosis, scar, or inflammation, and misses metabolically active disease within nodes of normal size. CT remains complementary to rather than competitive with PET.
• Whole-body MRI — Particularly valuable for bone marrow evaluation (haematological malignancies, multiple myeloma) and soft tissue characterisation. NICE recommends whole-body MRI over FDG-PET for initial myeloma staging. Diffusion-weighted MRI (DW-MRI) provides functional information analogous to PET without ionising radiation. Limited by scan time (60–90 minutes), patient tolerance, and inferior detection of small pulmonary nodules.
• 99mTc-MDP bone scintigraphy (bone scan) — Lower cost alternative to 18F-NaF PET for skeletal metastasis detection. However, sensitivity is substantially lower than PET and requires a separate scan for soft tissue disease. Largely supplanted by PSMA PET/CT in prostate cancer and by FDG-PET/CT in breast cancer, lung cancer, and lymphoma staging workups.
• SPECT (Single Photon Emission Computed Tomography) — Lower spatial resolution functional imaging using single-photon emitting tracers (technetium, iodine-123, gallium-67). Applications include myocardial perfusion imaging (99mTc-sestamibi), thyroid cancer iodine scanning, and neuroendocrine tumour detection (111In-Octreotide). Generally lower sensitivity and resolution than PET but more widely available and less expensive.
• Liquid biopsy (circulating tumour DNA) — Emerging non-imaging alternative for treatment response monitoring in certain cancers, detecting tumour-specific genetic alterations in plasma with high sensitivity. Not a spatial imaging tool but may complement or eventually replace some serial PET response assessments.